Obesity is an important independent risk factor for cardiovascular diseases,remaining an important health concern worldwide.Evidence shows that saturated fatty acid-induced inflammation in cardiomyocytes contributes to obesity-related cardiomyopathy.Dapagliflozin(Dapa),a selective SGLT2 inhibitor,exerts a favorable preventive activity in heart failure.In this study,we investigated the protective effect of Dapa against cardiomyopathy caused by high fat diet-induced obesity in vitro and in vivo.Cultured rat cardiomyocyte H9c2 cells were pretreated with Dapa(1,2.5 μM)for 1.5 h,followed by treatment with palmitic acid(PA,200 uM)for 24 h.We showed that Dapa pretreatment concentration-dependently attenuated PA-induced cell hypertrophy,fibrosis and apoptosis.Transcriptome analysis revealed that inhibition of PA-activated MAPK/AP-1 pathway contributed to the protective effect of Dapa in H9c2 cells,and this was confirmed by anti-p-cJUN fluorescence staining assay.Using surface plasmon resonance analysis we found the direct binding of Dapa with NHE1.Gain and loss of function experiments further demonstrated the role of NHE1 in the protection of Dapa.In vivo experiments were conducted in mice fed a high fat diet for 5 months.The mice were administered Dapa(1 mg·kg-1·d-1,i.g.)in the last 2 months.Dapa administration significantly reduced the body weight and improved the serum lipid profiles.Dapa administration also alleviated HFD-induced cardiac dysfunction and cardiac aberrant remodeling via inhibiting MAPK/AP-1 pathway and ameliorating cardiac inflammation.In conclusion,Dapa exerts a direct protective effect against saturated fatty acid-induced cardiomyocyte injury in addition to the lowering effect on serum lipids.The protective effect results from negative regulating MAPK/AP-1 pathway in a NHE1-dependent way.The current study highlights the potential of clinical use of Dapa in the prevention of obesity-related cardiac dysfunction.

Ke Lin;Na Yang;Wu Luo;Jin-fu Qian;Wei-wei Zhu;Shi-ju Ye;Chen-xin Yuan;Di-yun Xu;Guang Liang;Wei-jian Huang;Pei-ren Shan

Department of Cardiology,The Key Lab of Cardiovascular Disease of Wenzhou,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou 325035,China;Chemical Biology Research Center,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou 325035,China

中国药理学报（英文版）

[1]Ke Lin;Na Yang;Wu Luo;Jin-fu Qian;Wei-wei Zhu;Shi-ju Ye;Chen-xin Yuan;Di-yun Xu;Guang Liang;Wei-jian Huang;Pei-ren Shan-.Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling)[J].中国药理学报（英文版）,2022(10):2624-2635

Dapagliflozin,uM,cJUN

Direct,protection,against,obesity,related,cardiomyopathy,NHE1,MAPK,signaling,Obesity,important,independent,risk,cardiovascular,diseases,remaining,health,concern,worldwide,Evidence,shows,that,saturated,fatty,acid,induced,inflammation,cardiomyocytes,contributes,selective,SGLT2,inhibitor,exerts,favorable,preventive,activity,heart,failure,In,this,study,investigated,protective,effect,caused,by,diet,vitro,vivo,Cultured,H9c2,cells,were,pretreated,followed,palmitic,PA,We,showed,pretreatment,concentration,dependently,attenuated,hypertrophy,fibrosis,apoptosis,Transcriptome,analysis,revealed,inhibition,activated,pathway,contributed,was,confirmed,anti,fluorescence,staining,assay,Using,surface,plasmon,resonance,found,direct,binding,Gain,loss,experiments,further,demonstrated,role,conducted,mice,fed,months,administered,last,administration,significantly,reduced,body,weight,improved,serum,profiles,also,alleviated,HFD,cardiac,dysfunction,aberrant,remodeling,inhibiting,ameliorating,conclusion,injury,addition,lowering,lipids,results,from,negative,regulating,current,highlights,potential,clinical,prevention

0.485196